Thrombotic thrombocytopenic pupura (TTP) is a life-threatening disease characterised by microangiopathic haemolytic anaemia, consumptive thrombocytopenia and various organ dysfunctions, such as neurological symptoms, renal damage and fever.
glycoprotein produced within the vascular endothelial cells and the megakaryocytes. In its multimer form, vWF has maximal capacity to aggregate and bind blood platelets. Under normal conditions, increased platelet aggregation is prevented by cleavage of the vWF multimers. Tsai et al. 6 and Furlan et al. 7 independently identified a vWF-cleaving protease (ADAMTS13) missing from the plasma of patients with congenital TTP 8 and severely deficient in patients with acquired idiopathic TTP.
Mutations in the ADAMTS13 gene were shown to cause congenital TTP, 9 so far more than 90 mutations of the ADAMTS13 gene have been described. 3 Much more common than hereditary TTP is the idiopathic form of TTP caused by auto-antibodies. These inhibitory antibodiesmostly immunoglobulin G (IgG) antibodies -bind to the cystine-rich domain of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) and lead to a decreased function of the enzyme. 10, 11 The major role of B cells in the production of inflammatory cytokines and auto-antibodies, as well as the ability to act as antigen-presenting cells, is the basis for B-cell-depleting therapies in immune-mediated disorders. Due to the autoimmune nature of acquired idiopathic TTP, rituximab has been used as a second-line immunosuppressive intervention in TTP cases refractory to plasma exchange as well as in frequently relapsing patients. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen present on B lymphocytes, is used in lymphoma therapy as well as in autoimmune diseases such as rheumatoid arthritis and immune thrombocytopenia. Its effect relies on clearance of B lymphocytes by complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity or directly by inducing apoptosis. However, several lines of evidence indicate that the T-cell compartment may also be modulated by these interventions. 22, 23 multimers as well as auto-antibodies to ADAMTS13 and replacing the vWF-cleaving protease activity. 26, 27 Therapeutic plasma exchange is the only therapy for TTP with proven efficacy in prospective randomised clinical trials. The Canadian Apheresis Study Group compared plasma infusion (30ml/kg initially, then 15ml/kg daily) with plasma exchange (1.5 plasma volume/day for ten days, then one plasma volume/day) and demonstrated increased survival in the plasma exchange arm (78 versus 63%). 25 Other studies reported similar results. 28 As a result of this therapeutic intervention the overall survival could be improved from 10% to more than 80%. 29, 30 However, up to one-third of patients relapse after successful treatment of an acute episode, and especially patients who present initially with severe ADAMTS13 deficiency have a significantly increased risk of relapsing TTP. 26, 31 In case of plasma-refractory TTP, which is defined as persistent thrombocytopenia or lactate dehydrogenase elevation after a total of seven daily plasma exchange procedures, current guidelines advise to intensify plasma exchange and to add corticosteroids. 27 The advice of additional corticosteroids is mainly two-thirds because of refractory disease to standard treatment and one-third because of recurrent disease. More than 90% of patients achieved complete remission after rituximab. In the reported cases, only 10-13% of patients relapsed after rituximab treatment after a median follow-up of 11 months. 13, 14 Further research should focus on long-term follow-up, especially when considering that B-cell recovery typically occurs nine to 12 months after rituximab application. Longer follow-up is required to address the possible long-term side effects of rituximab and the overall safety of this treatment. 36 Moreover, despite the initial high response rates after rituximab treatment, longer follow-up periods are required to assess the exact benefit of this therapy and also to take into account late relapses.
Long-term Follow-up After Rituximab Treatment
To address these concerns in our patient cohort, we re-evaluated all patients with non-familial idiopathic TTP refractory to plasma At the time of initial TTP diagnosis, the median age of the 12 patients was 42.5 years, and 75% of patients were female. At presentation, the mean platelet count was decreased to 19.8 x 10 9 /l and mean lactate dehydrogenase (LDH) was elevated to 1018U/l (reference <250U/l).
All patients had plasma exchange with fresh frozen plasma and steroid treatment prior to rituximab, and four patients had been additionally treated with vincristine (2mg intravenous). Seven patients were treated during the first episode of acute TTP, among whom five received rituximab because of an insufficient response to standard therapy with plasma exchange: two patients suffered from severe allergic reaction leading to disruption of plasma exchange after 22 and 10 exchange procedures, respectively. Five patients received rituximab because of relapse after at least one prior episode of acute TTP initially successfully treated with standard therapy. Baseline characteristics of all patients are shown in Table 1 . Due to assay availability, unfortunately only in a minority of patients, ADAMTS13
activity was analysed before initiation of rituximab therapy. After application of rituximab, no severe acute side effects were noted and all patients responded with complete remission. This is in line with previous data reporting acute response rates of >90%. 26, 34 After nearly 50 months follow-up, three of 12 patients had relapsed.
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Treatment of Further Relapse after Rituximab Treatment
Treatment decision-making in the case of further relapse after rituximab is difficult and not evidence-based. Rituximab has been used as pre-emptive treatment in patients with anti-ADAMTS13 autoantibodies, 38 and rituximab maintenance may be an option in these patients. However, this has to be weighed against potential long-term side effects, such as progressive multifocal leucoencephalopathy. 39 An alternative treatment would be a splenectomy, which is supported by data provided by Kappers-Klunne et al. 40 Thirty-three patients with TTP were retrospectively reported who were splectomised due to refractory or relapsing disease. After median follow-up of 109 months the 10-year relapse-free survival was 70%. As these data were generated without rituximab being a treatment alternative, one has to balance the risks of the operation procedure, post-operative complications and infectious complications post-splenectomy against the consequences of long-term B-cell depletion during rituximab maintenance therapy.
Safety Considerations
In our patient collective, no treatment-related, especially infectious, complications were reported. In all but two patients, B-cell counts had recovered at the end of follow-up, and one of these two patients is currently treated with rituximab maintenance therapy. This is congruent with previous reports using rituximab in relapsing or refractory TTP. Rituximab is usually well tolerated and acute reactions are usually mild without causing discontinuation of the drug. 
